Combination therapy with reovirus and Anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses

Molecular Therapy

Volumn 24, Issue 1, 2016, Pages 166-174

  Rajani, Karishma ^a   Parrish, Christopher ^b   Kottke, Timothy ^a   Thompson, Jill ^a   Zaidi, Shane ^a   Ilett, Liz ^b   Shim, Kevin G ^a   Diaz, Rosa Maria ^a   Pandha, Hardev ^c   Harrington, Kevin ^d   Coffey, Matt ^e   Melcher, Alan ^b   Vile, Richard ^a,f  

^a MAYO CLINIC   (United States)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e ONCOLYTICS BIOTECH INC   (Canada)

^f MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GAMMA INTERFERON; PROGRAMMED CELL DEATH 1 ANTIBODY; UNCLASSIFIED DRUG; ONCOLYTIC VIRUS; PROGRAMMED DEATH 1 RECEPTOR;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL KILLING; CONTROLLED STUDY; CYTOKINE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; REGULATORY T LYMPHOCYTE; REOVIRIDAE; SURVIVAL; TH1 CELL; TUMOR CELL; TUMOR GROWTH; ANIMAL; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; MORTALITY; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES; COMBINED MODALITY THERAPY; IMMUNITY, INNATE; MELANOMA, EXPERIMENTAL; MICE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROGRAMMED CELL DEATH 1 RECEPTOR; REOVIRIDAE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84957845897     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.156     Document Type: Article

References (42)

1. Thirukkumaran, CM, Nodwell, MJ, Hirasawa, K, Shi, ZQ, Diaz, R, Luider, J., et al. (2010). Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res 70: 2435-2444
2. Twigger, K, Roulstone, V, Kyula, J, Karapanagiotou, EM, Syrigos, KN, Morgan, R., et al. (2012). Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer 12: 368
3. Errington, F, Steele, L, Prestwich, R, Harrington, KJ, Pandha, HS, Vidal, L., et al. (2008). Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 180: 6018-6026
4. Prestwich, RJ, Ilett, EJ, Errington, F, Diaz, RM, Steele, LP, Kottke, T., et al. (2009). Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 15: 4374-4381
5. Qiao, J, Wang, H, Kottke, T, White, C, Twigger, K, Diaz, RM., et al. (2008). Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 14: 259-269
6. Kottke, T, Thompson, J, Diaz, RM, Pulido, J, Willmon, C, Coffey, M., et al. (2009). Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res 15: 561-569
7. Kottke, T, Hall, G, Pulido, J, Diaz, RM, Thompson, J, Chong, H., et al. (2010). Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest 120: 1551-1560
8. Prestwich, RJ, Errington, F, Ilett, EJ, Morgan, RS, Scott, KJ, Kottke, T., et al. (2008). Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 14: 7358-7366
9. Comins, C, Spicer, J, Protheroe, A, Roulstone, V, Twigger, K, White, CM., et al. (2010). REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 16: 5564-5572
10. Galanis, E, Markovic, SN, Suman, VJ, Nuovo, GJ, Vile, RG, Kottke, TJ., et al. (2012). Phase II trial of intravenous administration of Reolysin(?) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther 20: 1998-2003
11. Harrington, KJ, Karapanagiotou, EM, Roulstone, V, Twigger, KR, White, CL, Vidal, L., et al. (2010). Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 16: 3067-3077
12. Roulstone, V, Khan, K, Pandha, HS, Rudman, S, Coffey, M, Gill, GM., et al. (2015). Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Clin Cancer Res 21: 1305-1312
13. Vidal, L, Pandha, HS, Yap, TA, White, CL, Twigger, K, Vile, RG., et al. (2008). A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 14: 7127-7137
14. White, CL, Twigger, KR, Vidal, L, De Bono, JS, Coffey, M, Heinemann, L., et al. (2008). Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 15: 911-920
15. Harrington, KJ, Vile, RG, Melcher, A, Chester, J and Pandha, HS (2010). Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 21: 91-98
16. Gollamudi, R, Ghalib, MH, Desai, KK, Chaudhary, I, Wong, B, Einstein, M., et al. (2010). Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 28: 641-649
17. Nishimura, H, Okazaki, T, Tanaka, Y, Nakatani, K, Hara, M, Matsumori, A., et al. (2001). Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291: 319-322
18. Francisco, LM, Sage, PT and Sharpe, AH (2010). The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236: 219-242
19. Probst, HC, McCoy, K, Okazaki, T, Honjo, T and Van den Broek, M (2005). Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 6: 280-286
20. Keir, ME, Butte, MJ, Freeman, GJ and Sharpe, AH (2008). PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26: 677-704
21. Freeman, GJ, Long, AJ, Iwai, Y, Bourque, K, Chernova, T, Nishimura, H., et al. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-1034
22. Ahmadzadeh, M, Johnson, LA, Heemskerk, B, Wunderlich, JR, Dudley, ME, White, DE., et al. (2009). Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114: 1537-1544
23. +tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124: 2246-2259
24. Dong, H, Strome, SE, Salomao, DR, Tamura, H, Hirano, F, Flies, DB., et al. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800
25. Schreiber, RD, Old, LJ and Smyth, MJ (2011). Cancer immunoediting: integrating immunitys roles in cancer suppression and promotion. Science 331: 1565-1570
26. McDermott, DF and Atkins, MB (2013). PD-1 as a potential target in cancer therapy. Cancer Med 2: 662-673
27. Zou, W and Chen, L (2008). Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8: 467-477
28. Naidoo, J, Page, DB and Wolchok, JD (2014). Immune modulation for cancer therapy. Br J Cancer 111: 2214-2219
29. Brahmer, JR, Drake, CG, Wollner, I, Powderly, JD, Picus, J, Sharfman, WH., et al. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167-3175
30. Brahmer, JR, Tykodi, SS, Chow, LQ, Hwu, WJ, Topalian, SL, Hwu, P., et al. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465
31. Stanford, MM, Breitbach, CJ, Bell, JC and McFadden, G (2008). Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?. Curr Opin Mol Ther 10: 32-37
32. Melcher, A, Parato, K, Rooney, CM and Bell, JC (2011). Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 19: 1008-1016
33. Zamarin, D, Holmgaard, RB, Subudhi, SK, Park, JS, Mansour, M, Palese, P., et al. (2014). Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6: 226ra32
34. Engeland, CE, Grossardt, C, Veinalde, R, Bossow, S, Lutz, D, Kaufmann, JK., et al. (2014). CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther 22: 1949-1959
35. Sorensen, MR, Holst, PJ, Steffensen, MA, Christensen, JP and Thomsen, AR (2010). Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine 28: 6757-6764
36. Altomonte, J and Ebert, O (2012). Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses. Microb Biotechnol 5: 251-259
37. Diaz, RM, Galivo, F, Kottke, T, Wongthida, P, Qiao, J, Thompson, J., et al. (2007). Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 67: 2840-2848
38. Galivo, F, Diaz, RM, Thanarajasingam, U, Jevremovic, D, Wongthida, P, Thompson, J., et al. (2010). Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther 21: 439-450
39. Wongthida, P, Diaz, RM, Galivo, F, Kottke, T, Thompson, J, Pulido, J., et al. (2010). Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res 70: 4539-4549
40. Kottke, T, Galivo, F, Wongthida, P, Diaz, RM, Thompson, J, Jevremovic, D., et al. (2008). Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol Ther 16: 1217-1226
41. Tumeh, PC, Harview, CL, Yearley, JH, Shintaku, IP, Taylor, EJ, Robert, L., et al. (2014). PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515: 568-571
42. Karyampudi, L, Lamichhane, P, Scheid, AD, Kalli, KR, Shreeder, B, Krempski, JW., et al. (2014). Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res 74: 2974-2985